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Increasing resistance to antibiotics creates the need for prudent
antibiotic use. When resistance to various antibiotics within a class
is driven by stepwise accumulation of mutations, a dilemma may
exist in regard to replacing an antibiotic that is losing effectiveness
due to resistance with a new drug within the same class. Such
replacement may enhance treatment success in the short term but
promote the spread of highly resistant strains. We used mathe-
matical models to quantify the tradeoff between minimizing
treatment failures (by switching early) and minimizing the prolif-
eration of the highly resistant strain (by delaying the switch).
Numerical simulations were applied to investigate the cumulative
prevalence of the highly resistant strain (Resistance) and the
cumulative number of treatment failures (Failure) that resulted
from following different antibiotic use policies. Whereas never
switching to the new drug always minimizes Resistance and
maximizes Failure, immediate switching usually maximizes Resis-
tance and minimizes Failure. Thus, in most circumstances, there is
a strict tradeoff in which early use of the new drug enhances
treatment effectiveness while hastening the rise of high-level
resistance. This tradeoff is most acute when acquired resistance is
rare and the highly resistant strain is readily transmissible. How-
ever, exceptions occur when use of the new drug frequently leads
to acquired resistance and when the highly resistant strain has
substantial ‘‘fitness cost’’; these circumstances tend to favor an
immediate switch. We discuss the implications of these con-
siderations in regard to antibiotic choices for Streptococcus
pneumoniae.
antibiotic resistance  fluoroquinolones  mathematical models 
optimization
Antimicrobial resistance is a growing threat to public health inboth developed and developing countries (1, 2). The emer-
gence and spread of resistance demonstrates the ecological and
evolutionary response of bacterial species to the selection pressure
imposed by widespread use of antibiotics (3). In a variety of species,
the discovery and widespread clinical use of an antimicrobial drug
has been followed by the emergence of resistant strains, frequently
creating the need for still newer drugs. This ‘‘arms race’’ between
bacterial resistance and antimicrobial innovations presents a stra-
tegic question: When should a drug that is losing effectiveness due
to rising resistance be replaced with a novel drug in the same or
different class (e.g., replacing gentamicin with amikacin in hospital
settings) (4, 5)? Antibiotic policies in general, and specifically the
decision concerning a change in prescribing practices, have two
objectives: (i) to improve treatment effectiveness for the current
population and (ii) to prevent the emergence of higher-level
resistance in the future.
In the case of two antibiotics with distinct mechanisms of action,
theoretical and empirical research supports the merits of combi-
nation therapy to both prevent treatment failure in individuals and
control antimicrobial resistance at the population level; in other
words, the same policy may satisfy both objectives (6–8). In other
cases, the two objectives may be in conflict. For a bacterial pathogen
that is increasingly resistant to a widely prescribed agent, promoting
the use of a novel drug with activity against the resistant strains
leads to fewer treatment failures and delivers benefits to current
patients (4, 9). On the other hand, switching to a new drug imposes
a selective pressure in favor of strains that are resistant to even the
new antibiotic (10–12). Thus, we may expect that such a switch
achieves the first objective at the expense of the second. Specifically,
when considering two antibiotics within the same therapeutic class,
high-level resistance is often conferred through sequential accu-
mulation of chromosomal mutations or acquisition of new genetic
material (8). This stepwise mechanism makes combination therapy
or cycling of two antibiotics of the same class impractical. For
example, resistance to fluoroquinolones in Streptococcus pneu-
moniae is mediated by chromosomal changes on two genes: DNA
gyrase (gyrA) and topoisomerase IV (parC) (13). The first gener-
ation of fluoroquinolones, such as ofloxacin and ciprofloxacin,
preferentially targets one of the two loci. Since 1994, however, a
number of newer ‘‘dual-activity’’ fluoroquinolones, including levo-
floxacin (the second generation) and gatifloxacin and moxifloxacin
(the third generation) (14), that demonstrate more comparable
activity against both genes, have been developed. Because at least
two mutations are usually required in order to confer a biologically
significant resistance to these newer agents, the likelihood for a
resistant strain to emerge during treatment of a fully susceptible
infection is much lower (15–17). On the other hand, a strain already
resistant to an ‘‘old’’ fluoroquinolone is only one mutation away
from becoming resistant to the newer drugs, making selection of a
fully resistant mutant more likely from such ‘‘precursor’’ strains.
In the presence of such a stepwise mechanism, does treatment
success for today’s patients still inevitably lead to faster selection of
resistance? It may do so, as argued above; however, a contrasting
argument runs as follows: Because strains resistant to the older
fluoroquinolones are the genetic precursors to higher-level resis-
tance, early upgrade to the new agents could ‘‘block’’ the pathway
toward selecting for highly resistant strains (18). Early use of the
newer drugs also presents immediate benefits to patients. There-
fore, an immediate switch to the more active drugs could achieve
both better outcomes today and slower evolution of resistance
tomorrow.
In upgrading the drug of choice for empiric therapy, determining
whether the two objectives are consistent or in conflict requires a
specific quantitative model. We evaluate this possible tradeoff by
using a mathematical model to simulate the dynamics of commensal
bacteria possessing a stepwise genetic basis for resistance. We
consider the transmission dynamics of three strains: (i) drug-
sensitive, (ii) resistant to the old drug but sensitive to the new drug,
and (iii) resistant to both drugs. We ask how the timing of a
population-wide switch from the old drug to the new drug affects
two objectives. The first objective is to minimize the cumulative
prevalence of highly resistant strains over time and is defined
mathematically by using aResistance function. The second objective
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is to minimize the cumulative number of ineffective treatment
episodes (defined by using aFailure function). We examine whether
the two objectives are at all times incompatible, that is, whether an
early switch to the new drug will decrease Failure and inevitably
increase Resistance or, on the other hand, whether delayed switch
will slow the rise of Resistance at the cost of more Failure over time.
Previous models of antibiotic policies have mostly focused on either
curbing the overall presence of resistant bacteria (19–22) or min-
imizing the total burden of infection (23) by managing two or more
classes of drugs. To the best of our knowledge, no prior study has
highlighted the possible conflict in regard to updating antibiotic
formularies within the same class.
Results
Qualitative Results. Fig. 1 illustrates the effect of a population-wide
switch to the new drug on each of the two outcomes:Resistance and
Failure. Early adoption of the new drug (policy A) allows more time
for the highly resistant strain, Y2, to spread (i.e., ‘‘primary resis-
tance’’) with suppressed competition from the less resistant strains:
the wild-type, Y0, and the low-level resistant strain, Y1. In contrast,
delaying the switch (policy B) allows more accumulation of Y1 from
treating Y0 hosts with the old drug and from permitting the spread
of Y1 without hindrance from the new drug. Because Y1 is a
precursor of Y2, more Y1 in the population leads to the emergence
of more Y2 (‘‘acquired resistance’’) once the switch is made at a
later time (as shown in Fig. 1a). If the primary mechanism is more
prominent than the acquired mechanism, then an immediate switch
will lead to more cumulative presence of Y2 (higherResistance) than
a delayed switch. On the other hand, if the acquired mechanism
dominates, a delayed switch could result in rapid accumulation of
Y2 after the switch and eventually lead to more resistance.
Contributions of ineffective patient–drug encounters to the
Failure function are driven by similar counterbalancing effects (Fig.
1b). The most apparent benefit of instant switching is that of
avoiding treatment failures among treated Y1 hosts. However,
treatment failures may later begin to accumulate rapidly as a result
of the rise of the highly resistant strain. If the initial prevalence of
Y1 is high, the immediate benefit of switching to the new drug will
be quite large. However, if early switching to the new drug greatly
fosters the emergence of Y2, mainly from primary resistance
(transmission), the cumulative ineffective treatment episodes can
surge after the switch and, eventually, offset its early benefit. These
observations indicate that the tradeoff between the consequences
depends on the relative magnitude of multiple countervailing
effects of an antibiotic switching policy on population dynamics.
Quantitative Results: Numerical Simulations. On the basis of 2,000
random parameter sets (summarized in Table 1) chosen from our
structured sampling process, the switch timings that result in the
highest and lowest values of Resistance and Failure functions are
summarized in Table 2 and as follows.
Result 1: Never switching to the new drug always minimizes Resistance. In
all 2,000 sample scenarios, the policy to minimize Resistance is to
never use the new drug (Table 2). Fig. 3, which is published as
supporting information on the PNAS web site, illustrates typical
trajectories of such scenario. We note that such a policy, although
theoretically possible, is unlikely in practice. Because the use of the
novel drug will always be beneficial for at least some patients,
intentionally withholding a better (and assumedly safe and afford-
able) drug is unrealistic. Any feasible strategy to designate its best
use, even with very restricted use, will lead to some selection
pressure for the development of resistance.
Result 2: Immediate switching maximizes Resistance in most, but not all,
scenarios. Immediate switching results in the greatest Resistance in
1,767 of 2,000 scenarios. Immediately after the switch, the use of the
new drug curbs the ascent of Y1 while promoting Y2. In these cases,
the earlier the switch the greater the selection pressure for the
highly resistant strain over time (e.g., Fig. 3).
Result 3: Delayed switching maximizes Resistance in certain scenarios.
Immediate switching did not maximize Resistance in 233 (11.65%)
of 2,000 scenarios. In these less typical scenarios, the increase in Y2
after a delayed switch is greater than that after an immediate switch
because delayed switch produces a larger pool of the Y2 precursor,
Y1, and subsequently leads to rapid appearance of Y2 when the
switch takes place (e.g., Fig. 4, which is published as supporting
information on the PNAS web site).
Result 4: Never switching always results in the most Failure. Because (by
assumption) Y1 is more prevalent than Y2 at baseline and has a
lower ‘‘fitness cost,’’ never replacing the old drug leads to more
initial failures and exacerbates the problem by continuing selection
to increase the prevalence of Y1 (e.g., Fig. 5, which is published as
supporting information on the PNAS web site).
Result 5: Immediate switching minimizes Failure in most, but not all,
scenarios. Failure is minimized by immediate switching in 1,933
(96.65%) of 2,000 scenarios. In these more typical scenarios, the
benefit of an immediate switch by effectively treating Y1 strains
outweighs the cost of promoting Y2.
Result 6: Delayed switching minimizes Failure in a small number of
scenarios. In 67 (3.35%) of 2,000 scenarios, delayed switching results
in less failure than immediate switching. This result occurs when the
Fig. 1. Qualitative description of the dynamics of the low-level resistant strain
(Y1) and the highly resistant strain (Y2) under two different antibiotic-switching
policies. The contents of each ‘‘barrel’’ represent the amount and composition of
each strain, by mechanisms of emergence (acquired vs. primary). Xs indicate
inhibition or blockage. Policy A (immediate switch) uses the new drug in both
periods 1 and 2, whereas policy B (delayed switch) uses the old drug in period 1
andswitches tothenewdrugat thebeginningofperiod2.Theobjective function
Resistance (a) accumulates the presence of Y2 over both periods, whereas Failure
(b) counts failed treatment episodes among treated hosts. (b) is the same as (a),
only recoded to indicate treatment outcomes.
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rapid escalation of Y2 after the switch outweighs the benefit of
eliminating treatment failures from treated Y1 hosts (e.g., Fig. 6,
which is published as supporting information on the PNAS web
site).
Determinants of Atypical Results. We compared parameter sets that
led to the ‘‘typical’’ results described in the previous section with sets
that generated ‘‘atypical’’ results (results 3 and 6 in the previous
section), as summarized in Table 3.
When delayed switching maximizes Resistance. Based on our qualitative
analysis of the system, we found that delaying switching will
maximize Resistance (result 3, as opposed to the more common
result 2 in which immediate switching maximizes Resistance) when
acquisition of high-level resistance during treatment (the Y13 Y2
transiton) is the dominant process in producing highly resistant
strains. This result occurs when the delay leads to a large increase
in Y1 and when the new drug selects for Y2 easily from this enlarged
pool of Y1. Among the atypical scenarios (N  233), parameters
involved in the acquired mechanism for resistance [i.e., e12, P, and
Y1(0)] have means significantly higher than among the typical
scenarios. Specifically, e12 represents the likelihood of this selection
and is shown to best differentiate an atypical scenario from a typical
one (C-statistic  0.924). In contrast, acquisition of Y2 through
transmission (primary resistance) is less important in these scenar-
ios, because few Y2 are present at the start or because the Y2 strain
has low transmissibility (low relative fitness). In other words, in
settings where the highly resistant strain transmits poorly but can be
readily selected for among hosts with first-step mutants, it might be
beneficial to begin using the new drug early, even for the purpose
of preventing high-level resistance from emerging.
When immediate switching increases Failure. According to our quali-
tative analysis, immediate switching could increaseFailure (result 6)
when the increased transmission of Y2 due to the switch outweighs
the early improvement in the outcome of treatment. Larger values
of f2 and Y2(0) among the atypical Failure scenarios reflect this
point because more, fitter Y2 strains increase the opportunity for Y2
transmission after the switch. Both parameters are good predictors
of such scenarios (C-statistic  0.882 and 0.707, respectively).
Interestingly, a higher level of use of drugs from this class (P)
correlates with the occurrence of both atypical Failure results and
atypical Resistance results. Because a large P indicates both a high
rate of using the old drug before the switch and high rate of using
the new drug after the switch, its net effect on the balance of
acquired vs. primary mechanism of Y2 emergence is vague and
must, in practice, depend on its combination with other parameters.
Finally, note the somewhat counterintuitive observations that the
values of f1 and Y1(0) are also significantly higher in the atypical
scenarios. This result may reflect constraints imposed during our
sampling process, in which we select only parameter sets that satisfy
f1  f2 and Y1(0)  Y2(0).
Sensitivity Analyses on Model Assumptions. Clinical experience with
older and newer fluoroquinolones has suggested the need to
examine possible deviations from two of our model assumptions. In
a handful of cases of fluoroquinolone treatment failure, acquired
double-mutants (Y2) have emerged from patients originally carry-
ing wild-type pneumococcal isolates during therapy with cipro-
floxacin or levofloxacin (24). These cases suggest that a potential
transition, Y0 3 Y2, which was not accounted for in our model,
might play a significant role in clinical treatment failures. In
addition, because the minimal inhibitory concentration (MIC) of
bacterial strains is continuous and the first-step mutation (Y1) often
does not result in sufficient MIC increase to confer clinically
meaningful resistance to the old drugs (e.g., ciprofloxacin), the old
drug may also select for highly resistant strains among treated
carriers of the first-step mutant, i.e., the Y13 Y2 transition during
therapy with the old drug (24).
We examined the effect on our main results of allowing the
occurrence of the above two transitions. Results are presented in
Table 4, which is published as supporting information on the
PNAS web site. In general, the more frequently these transitions
take place, the more the highly resistant strain is promoted by the
old drug and the more favorable immediate switching becomes
for the Resistance objective (it was already favorable for the
Failure objective). This finding is particularly true if Y2 emerges
frequently during treatment from carriers of the drug-sensitive
strain (Y0 3 Y2).
Table 1. Summary of parameter sampling ranges, constraining conditions, and resulting 2,000 parameter sets
Symbol Variable Range Rationale Final mean (range)
X(0) Proportion of population with no carriage (X) at time 0 0.5–1 Prevalence of S. pneumoniae from
surveillance (51)
0.7469 (0.5–0.9998)
f1 Relative fitness in transmissibility of Y1 (vs. Y0) 0.5–1 Unknown in humans (37) 0.9756 (0.9357–1)
f2 Relative fitness in transmissibility of Y2 (vs. Y0) f1(0.5–1)† Unknown in humans (37) 0.9527 (0.8788–0.9989)
e1 Probability of transition Y03Y1 when treated with the old drug 1e–6–1e–1* Treatment failure rate (24) 0.0086 (1.02e–6–0.01)
e12 Probability of transition Y13Y2 when treated with the new drug 1e–6–1e–1* Treatment failure rate (24) 0.0094 (1e–6–0.099)
P Proportion of population receiving treatment of this class 0.005–0.2 Prescription rates in U.S. and
Hong Kong (52–54)
0.1481 (0.012–0.2)
Y1(0) Initial proportion Y1 among all carriers 0.01–0.1 Uncertain (24) 0.0562 (0.01–0.1)
Y2(0) Initial proportion Y2 among all carriers Y1(0)(0.01–1)† Uncertain (24) 0.0274 (0.0002–0.0987)
r Yearly rate of clearance of carriage in the absence of treatment 2.89 (constant) Reciprocal of the duration (18 wk)
of carriage (55)
2.89 (2.89–2.89)
0 Transmission rate of drug-sensitive strain (Y0) — Calculated by assuming approximate
equilibrium: 1/X  0/r (48)
4.022 (2.8907–5.7785)
T Time frame 50 (constant) Sufficiently larger than 1r 50
*e01 and e12 are sampled from log-uniform distributions, thus the exponent is uniformly distributed.
†Sampling for multipliers 1 to constrain f1  f2 and Y1(0)  Y2(0). The multipliers are uniformly distributed between the ranges indicated.
Table 2. Frequencies of drug policies that minimize or maximize
Resistance and Failure, based on the 2,000 sampled
parameter sets
Drug-switching
policy*
Resistance Failure
Best N
(%)
Worst N
(%)
Best N
(%)
Worst N
(%)
Never switch 2,000 (100) — — 2,000 (100)
Delayed switch — 233 (11.65) 67 (3.35) —
Immediate switch — 1,767 (88.35) 1,933 (96.65) —
*Never switch, use the old drug throughout the entire 50-year time frame;
Delayed switch, start from using the old drug, then switch to the new drug
sometime between time 0 and time 5; Immediate switch, switch from the old
drug to the new drug at time 0.
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Discussion
In the presence of a genetic hierarchy of resistance levels within an
antibiotic class, our study suggests that upgrading within the class
presents a nearly inevitable tradeoff between fostering resistance to
the new drug and enhancing treatment success. Facing a choice
between immediately upgrading and continuing the use of an old
drug despite declining efficacy, a decision-maker can choose the
former to maximize clinical success but (in general) only at the
expense of promoting resistance to the new drug.
Our results show that this tradeoff becomes less stringent when
the highly resistant strains have limited ability to transmit (25) and
the new drug has a high risk of promoting resistance to itself. In this
case, an immediate switch will lead to little transmission of the
highly resistant strain, and thus the harm of such a policy can be
overcome by avoiding the proliferation of the precursor strain that
is only one genetic change away from high-level resistance. Simi-
larly, if the old drug can create acquired resistance during treat-
ment, not only to itself but also to the new drug (as in our sensitivity
analyses), early switching also becomes more favorable. On the
other hand, if the new drug has a very low risk of selecting for
resistance from its precursor strains but is highly transmissible once
it is present, then reserving the newer drug until the old drug is no
longer effective could be the preferable strategy at the population
level.
How might such considerations apply to actual antibiotic–
bacterial combinations in current clinical use? Given the context in
which the model was developed, we focus on S. pneumoniae. First,
consider our motivating example: fluoroquinolones. For commu-
nity-acquired pneumonia, use of newer fluoroquinolones has been
suggested as a means of averting treatment failure (18, 26). Our
model suggests the risk that this benefit would come at the cost of
promoting high-level fluoroquinolone resistance; however, the
properties of these agents to date seem to minimize such risk.
Although resistance to newer fluoroquinolones has been reported
(27), high-level resistance remains largely associated with previous
treatment, and there has been only limited evidence of clonal
spread of fluoroquinolone-resistant pneumococci (10–13, 28).
These observations may imply a considerable fitness cost from
acquiring incremental mutations associated with high-level fluoro-
quinolone resistance, a finding recently confirmed in animal models
(28). If such a fitness cost is present and persists despite possible
compensatory evolution, then it might be possible to use the new
fluoroquinolones for an extended period of time before high-level
resistance becomes a problem.
A second example is low- vs. high-level resistance to -lactams in
pneumococci. Susceptibilities to penicillin in pneumococci form a
continuum, with MIC ranging from0.01gml to8gml (31).
Incremental increases in MIC are conferred by acquisition of
resistant alleles of three penicillin-binding protein genes, as well as
by other mutational and transformational changes. However, high-
dose amoxicillin has been shown to eradicate carriage of interme-
diately resistant, and even some highly resistant, pneumococci,
whereas lower-dose regimens are generally only active against
susceptible strains (MIC  0.1 gml) (32). This situation mirrors
the old drugnew drug scenario described in our analysis, with the
old drug corresponding to lower doses and the new drug corre-
sponding to higher doses of amoxicillin. We and others (32) have
suggested that high amoxicillin doses can maintain effectiveness
against, and retard the spread of, low-level resistant strains similar
to the Y1 strains in our model. Our model results also suggest that
the use of high doses may facilitate the spread of highly resistant
strains. Unlike fluoroquinolone resistance, however, an acquisition
of exogenous DNA is required to transform strains from moder-
ately to highly resistant; thus, emergence of a highly resistant strain
is rare during treatment with -lactams. The wide clonal spread of
highly resistant strains (33) suggests that these strains are not much
compromised in their fitness and are capable of spreading. The
existence of fit, highly resistant strains may imply compensatory
chromosomal changes (34, 35), because animal studies showed
pneumococcal strains as being greatly compromised in vivo upon
acquisition of high-level resistant alleles (36, 37). These character-
istics suggest that, in the case of amoxicillin, the policy that
maximizes treatment success (widespread use of higher doses) may
unfortunately foster the emergence of higher-level resistance at the
population level.
Our results should be interpreted in the context of the following
limitations. First, our model considered a simplified scenario.
Several factors not included in the model can be influential:
population characteristics (e.g., age structure and clustering), vac-
cines (which may reduce, at least temporarily, the burden of
resistance) (38–42), and the availability of drug sensitivity testing in
some settings. Second, we did not consider antibiotics of other
classes and crossresistance. For example, a high proportion of
penicillin-resistant pneumococci also showed reduced susceptibility
to fluoroquinolones (29, 43), meaning that use of one antibiotic
class may promote resistance to other classes. Third, we constrained
our parameter sets to a set of scenarios with very low fitness costs,
to ensure that it was possible for high-level resistance to spread.
Although there are no quantitative estimates of fitness costs for
fluoroquinolone resistance, it seems possible that the costs are
higher than the values considered here (36, 37), meaning that the
actual probability for using newer fluoroquinolones without exten-
Table 3. Parameter distribution by optimization result types and single-parameter C-statistics
Parameter
Highest Resistance* Lowest Failure†
Typical
(N  1,767)
Atypical
(N  233) C-statistic‡
Typical
(N  1,933)
Atypical
(N  67) C-statistic‡
X(0) 0.751 (0.144)§ 0.716 (0.138)§ 0.569 0.749 (0.144)¶ 0.699 (0.138)¶ 0.602
f1 0.976 (0.016) 0.975 (0.015) 0.513 0.975 (0.015)§ 0.996 (0.003)§ 0.936
f2 0.954 (0.024)§ 0.943 (0.021)§ 0.644 0.952 (0.023)§ 0.982 (0.011)§ 0.882
e01 0.008 (0.019)¶ 0.012 (0.022)¶ 0.570 0.009 (0.020) 0.011 (0.019) 0.524
e12 0.005 (0.014)§ 0.041 (0.030)§ 0.924 0.010 (0.020) 0.008 (0.017) 0.510
P 0.147 (0.041)§ 0.160 (0.031)§ 0.586 0.147 (0.040)§ 0.172 (0.023)§ 0.678
Y1(0) 0.057 (0.026)§ 0.047 (0.027)§ 0.609 0.056 (0.026) 0.063 (0.025) 0.578
Y2(0) 0.029 (0.022)§ 0.016 (0.016)§ 0.689 0.027 (0.021)§ 0.042 (0.022)§ 0.707
Typical and atypical results are presented as mean (SD).
*Typical results of highest Resistance occur with immediate switch, whereas atypical results occur with delayed switch.
†Typical results of lowest Failure occur with immediate switch, whereas atypical results occur with delayed switch.
‡Represents the area under the receiver-operating characteristic curve. A value of 1 indicates that the rank-order of the parameter
perfectly discriminates a typical from an atypical result; a value of 0.5 indicates no discriminatory power.
§Statistically significant difference in means at P  0.001.
¶Statistically significant difference in means at P  0.01.
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sive spread of high-level resistance could be higher. Fourth, al-
though the deterministic nature of the transmission model may be
appropriate for large host populations, the occurrence of a new
resistant strain is a stochastic process that was not accounted for.
Fifth, we have considered the simple question of when a complete
switch from an old drug to a new drug should be undertaken.
Additional work (data not shown) suggests that the results hold
even in the broader ‘‘policy space’’ by considering partial switching
(mixed use of the two drugs), but more complicated policies (e.g.,
multiple changes in the proportion of new vs. old drug over time)
have not been considered. Finally, we assumed that treating Y1
carriers with the old drug leads to clinical failure in all cases.
However, for fluoroquinolones such treatment may sometimes be
clinically successful (24). This assumption has pushed our results
toward favoring earlier switch.
Recent treatment guidelines include newer fluoroquinolones as
an option for initial empiric therapy for community-acquired
pneumonia in outpatient settings (18, 44, 45). More specifically,
although exact criteria vary, these guidelines recommend the first-
line use of these newer agents only for selected patients with
elevated clinical risk for carrying drug-resistant S. pneumoniae, such
as recent antibiotic use or cardiopulmonary disease. In the context
of our analysis, switching early to newer drugs to which little
resistance exists, but reserving them for use in severe cases, may
point to a way out of the dilemma suggested in this article. If the use
were kept below a level that limits the population-wide selection of
the highly resistant strain (22), then it might be possible to combine
a low failure rate for high-risk or the most severe cases (because the
new drug is used) with continued suppression of resistance (because
the drug is used sparingly). Such a strategy is especially reasonable
for a pathogen like S. pneumoniae, for which most antibiotic use is
for non-life-threatening conditions (e.g., otitis media), and evidence
suggests considerable fitness cost to high-level fluoroquinolone
resistance (28). The herd immunity exerted from the pneumococcal
conjugate vaccine has provided evidence that young children play
a key role in the transmission of pneumococci (46). However, most
invasive pneumococcal diseases cluster within a subpopulation (i.e.,
older adults). Reserving newer fluoroquinolones mainly for the
elderly, a group less central to the transmission of the organism, may
exert less selection pressure on the pneumococcal population while
providing considerable therapeutic benefits.
In conclusion, when the degree of resistance against various
antimicrobial agents in the same class is conferred in a stepwise
fashion, the choice of when to upgrade empiric therapy to a newer
agent faces a tradeoff between enhancing efficacy and preventing
resistance. This tradeoff is less stringent and favors more immediate
upgrade when the highly resistant strains are relatively unfit for
transmission and when the acquired resistance occurs frequently
under newer agents. A prudent approach to this decision would
prioritize use of the newer drug in patients at greatest risk for severe
outcomes and limit its use in individuals who contribute most to
transmission. Ongoing surveillance for phenotypic and genotypic
resistance, as well as periodic attempts to measure fitness burdens
on resistant strains, will help to keep such policies responsive to
bacterial evolution.
Methods
Mathematical Model. Fig. 2 illustrates our compartmental transmis-
sion model and the processes by which antibiotic use affects system
dynamics. At any time t, an individual resides in one of the four
carriage states: no carriage of any strain (X), colonized with the
drug-sensitive strain (Y0), colonized with the low-level resistant
strain (Y1), or colonized with the high-level resistant strain (Y2).
Noncarriers can be colonized asymptomatically from direct contact
with carriers and moved to Y0, Y1, or Y2 at rates proportional to the
prevalence and the transmissibility (0, 1, and 2) of each strain
(48). Spontaneous clearance of any carriage occurs at a rate r,
assumed equal for all strains.
Both the new drug and the old drug are active against the
wild-type strain. When a patient is treated with the old drug, the
mean clearance rate of the susceptible strain (Y0) is enhanced by
p1(t), which represents the incidence of old drug use and the extent
to which treatment shortens the duration of carriage. In a few (e01)
of these Y0 individuals treated with the old drug, the low-level
resistant strain (Y1) emerges during treatment. These bacteria are
resistant to the old drug but susceptible to the new drug. Use of the
new drug accelerates clearance of both the susceptible (Y0) and the
low-level resistant (Y1) strains by a rate p2(t), but it also selects for
the highly resistant (Y2) strain to emerge from a proportion (e12) of
the treated Y1 hosts. We assume that the treatment is empiric,
without drug sensitivity testing, as in many community-acquired
infections; thus, the rate at which an individual receives an antibiotic
is assumed to be independent of the drug sensitivity of the strain the
individual carries. We also assumed that the transition from Y0 to
Y2 is negligible (because multiple mutations in the same strain
occur at an exceedingly low rate), as is simultaneous carriage of
more than one strain. The transitions between these states can be
summarized by four ordinary differential equations:
X˙ 0XY0  1XY1  2XY2  p1 t1  e01Y0
 p2 t1  e12Y1  rY0  Y1  Y2
Y˙0  0XY0  p1 t  p2 t  rY0
Y˙1  1XY1  p2 t  rY1  p1 te01Y0
Y˙2  2XY2  rY2  p2 te12Y1.
Antibiotic Switching Policies. Mutually exclusive policy alternatives
can be defined by the course of p1(t) and p2(t) throughout a time
frame substantially longer than the average duration of carriage. As
a constraint (because the best way to minimize resistance is to
eliminate treatment), we assumed a constant total level of drug use
in this class, that is, p1(t)  p2(t) for all t. We further restricted our
attention to a subset of such functions that reflects a population-
wide upgrade on the drug of choice. We define any such policies by
parameter , such that
p1t P, 0 t	 0, t  .
Fig. 2. Structure of the compartmental two-drugthree-strain model. The
model describes the transmission dynamics in a closed population. Mathe-
matical expressions quantify the transition rates between indicated carriage
states. X represents no carriage; Y0, Y1, and Y2 represent hosts of the drug-
sensitive, low-level resistant, and highly resistant strains, respectively. Con-
stants include transmission rates (0, 1, and 2), probability of selection for Y1
among Y0 individuals treated with the old drug (e01), probability of selection
for Y2 among Y1 individuals treated with the new drug (e12), and rate (r) of
carriage clearance in the absence of treatment. The variables p1 and p2
represent population-level usage rates of the old and new drugs, respectively.
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For any policy, only the old drug is used until time , at which
point all incident prescriptions of this class are switched to the
new drug.
Potential Tradeoff: Resistance vs. Failure. We defined the first
objective, Resistance, mathematically as 0
TY2(t)dt to represent the
desire to minimize the cumulative prevalence of the highly resistant
strain over the course of T years. The Failure objective is defined as
the number of individuals being treated with a drug to which their
strain is not susceptible, or 0
T[p1(t)(Y1(t)Y2(t)) p2(t)Y2(t)]dt.
Numerical Simulation and Parameter Sampling. We adopted a nu-
merical simulation approach to explore whether the expected
conflict is always present or whether a plausible resolution provided
by immediate switching to the new drug may exist. Assuming a
50-year time frame and an 18-week duration of carriage, we
searched numerically for four  values: (i) a value that minimizes
Resistance, (ii) a value that maximizes Resistance, (iii) a value that
minimizes Failure, and (iv) a value that maximizes Failure. Had
there been a strict conflict between the two objectives, one would
anticipate that immediate switching to the new drug would mini-
mize Failure and maximize Resistance, whereas never using the new
drug would minimize Resistance at the cost of maximal Failure.
Constrained parameter sampling. We designed a random-sampling
algorithm to select 2,000 sets of input values to explore the optimal
and the worst policies with respect to the two objective functions,
within reasonable ranges of parameter values. A sample set consists
of eight parameters, each chosen randomly and independently from
a uniform distribution. Ranges for these distributions are based on
(when available) published literature on commensal bacteria such
as S. pneumoniae and the prescription trends of fluoroquinolones
in developed countries.
We imposed numeric constraints and exclusion criteria during
the selection process to ensure the dynamic of this biological system
to satisfy the following properties: (i) a fitness cost on a strain’s
transmissibility exists with each step of mutation conferring resis-
tance (35, 49, 50); (ii) carriage of any strain is asymptomatic and not
associated with noticeable excess mortality, therefore the popula-
tion size remains constant over time; (iii) the low-level resistant
strain is more prevalent than the highly resistant strain at time 0; (iv)
the epidemic of the bacteria is near equilibrium at time 0; and (v)
when the old drug is in exclusive use, the selection pressure is
sufficient to offset the fitness cost of Y1 relative to Y0, such that Y1
can prevail before switching; likewise, Y2 can prevail after switch-
ing. The resulting ranges of the parameters, and corresponding
distributions, are summarized in Table 1.
Software. Model construction, simulations, and optimization pro-
cedures were programmed in BERKELEY MADONNA (Modeling
and Analysis of Dynamic Systems, Version 8.1; R. I. Macey and
G. F. Oster, 2001, Univ. of California, Berkeley; www.berkeley-
madonna.com) and MATLAB (Student Version 6.5; MathWorks,
Natick, MA).
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